New ACC, AHA, HFSA Guidelines Recommend SGLT-2 Inhibitors for Symptomatic Heart Failure

The American College of Cardiology (ACC), American Heart Association (AHA) and Heart Failure Society of America (HSFA) have released a joint guideline addressing updates to heart failure prevention and treatment of symptomatic disease with the emerging SGLT-2 inhibitor drug class.

The new guideline—published and presented during the ACC 2022 Scientific Sessions in Washington DC—implement findings from trials including DAPA-HF and EMPEROR-HF, which previously shown the benefit of SGLT-2 inhibitors dapagliflozin and empagliflozin, respectively, in reducing composite cardiovascular events and mortality in patients with heart failure with reduced ejection fraction (HFrEF)—among other cardiovascular and cardiometabolic outcomes.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.